Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VALEANT PHARMACEUTICALS INTL INC T.VRX

Healthcare Drug Manufacturers - Specialty & Generic
"Valeant Pharmaceuticals is a global specialty pharmaceutical firm with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The firm also has a branded generics business that operates primarily in Latin America, Eastern Europe, and Asia."


TSX:VRX - Post by User

VALEANT PHARMACEUTICALS INTL INC > Morgan Stanley Analysts Give Valeant $42 Target
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Post by kthanxon Nov 09, 2016 3:15pm
198 Views
Post# 25441780

Morgan Stanley Analysts Give Valeant $42 Target

Morgan Stanley Analysts Give Valeant $42 TargetValeant Pharmaceuticals International Inc. (NYSE:VRX)received a $42.00 price target from Morgan Stanley in a report released on Tuesday. The brokerage currently has a a “buy” rating on the specialty pharmaceutical company’s stock. Morgan Stanley’s price target suggests a potential upside of 180.37% from the company’s current price.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities